NICE gives nod to pediatric hepatitis C products
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, looks set to give peginterferon alfa-2a (Pegasys, Roche) and peginterferon alfa-2b (ViraferonPeg, Merck Sharp & Dohme (MSD)), in combination with ribavirin, the thumbs up for treating children and young people with hepatitis C.